Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL

The Japan Adult Leukemia Study Group (JALSG) Ph+ALL202 study reported a high complete remission (CR) rate for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) patients treated with imatinib-combined chemotherapy. However, the long-term treatment efficacy remains uncertain. Here...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Hematol
Main Authors: Hatta, Yoshihiro, Mizuta, Shuichi, Matsuo, Keitaro, Ohtake, Shigeki, Iwanaga, Masako, Sugiura, Isamu, Doki, Noriko, Kanamori, Heiwa, Ueda, Yasunori, Yoshida, Chikamasa, Dobashi, Nobuaki, Maeda, Tomoya, Yujiri, Toshiaki, Monma, Fumihiko, Ito, Yoshikazu, Hayakawa, Fumihiko, Takeuchi, Jin, Kiyoi, Hitoshi, Miyazaki, Yasushi, Naoe, Tomoki
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2018
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6097750/
https://ncbi.nlm.nih.gov/pubmed/29694642
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-018-3323-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados